welcome
CNBC

CNBC

Health

Health

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

CNBC
Summary
Nutrition label

84% Informative

Johnson & Johnson's Spravato is now the first -ever standalone therapy for treatment-resistant depression.

The spray is on its way to becoming a blockbuster product, with the drug bringing in $780 million in sales during the first nine months of 2024 .

The drug is related to ketamine, a common anesthetic that can have hallucinogenic effects.

J&J began to market Spravato more heavily after in-person doctor visits became the norm again.

"The mental health community wasn't really used to doing procedures at that point. We weren't used to having a space set aside," Mattingly says.

"So many of us have become really strong advocates" for it, he says.